EJEva Julià

Eva Julià

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eva Julià has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Manuel Comabella

    Servei de Neurologia and Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d’Hebron (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

    10 shared publications
  • Xavier Montalban

    Centro de Esclerosis Múltiple de Cataluña y Departamento de Neurología, Hospital Universitario Vall d’Hebron, 08035 Barcelona, España

    9 shared publications
  • Jordi Río

    Servei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, Spain

    5 shared publications
  • Oscar Fornas

    Flow Cytometry Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology (BIST), Barcelona, Spain

    4 shared publications
  • Aitor Serres-Armero

    Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Barcelona, Spain

    2 shared publications
  • Alex Sánchez-Pla

    Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain

    2 shared publications

Latest Publications

  • Open Access

    Y chromosome sequence and epigenomic reconstruction across human populations

    by Paula Esteller-Cucala, Marc Palmada-Flores, Lukas F. K. Kuderna, Claudia Fontsere, Aitor Serres-Armero, Marc Dabad, María Torralvo, Armida Faella, Luis Ferrández-Peral, Laia Llovera, et al.

    Recent advances in long-read sequencing technologies have allowed the generation and curation of more complete genome assemblies, enabling the analysis of traditionally neglected chromosomes, such as the human Y chromosome (chrY). Native DNA was sequenced on a MinION Oxford Nanopore Technologies sequencing device to generate genome assemblies for seven major chrY human haplogroups. We analyzed and compared the chrY enrichment of sequencing data obtained using two different selective sequencing approaches: adaptive sampling and flow cytometry chromosome sorting. We show that adaptive sampling can produce data to create assemblies comparable to chromosome sorting while being a less expensive and time-consuming technique. We also assessed haplogroup-specific structural variants, which would be otherwise difficult to study using short-read sequencing data only. Finally, we took advantage of this technology to detect and profile epigenetic modifications among the considered haplogroups. Altogether, we provide a framework to study complex genomic regions with a simple, fast, and affordable methodology that could be applied to larger population genomics datasets.


  • Open Access

    Flow Sorting Enrichment and Nanopore Sequencing of Chromosome 1 From a Chinese Individual

    by Lukas F. K. Kuderna, Manuel Solís-Moruno, Laura Batlle-Masó, Eva Julià, Esther Lizano, Roger Anglada, Erika Ramírez, Alex Bote, Marc Tormo, Tomàs Marquès-Bonet, et al.

    Sorting of individual chromosomes by Flow Cytometry (flow-sorting) is an enrichment method to potentially simplify genome assembly by isolating chromosomes from the context of the genome. We have recently developed a workflow to sequence native, unamplified DNA and applied it to the smallest human chromosome, the Y chromosome. Here, we modify improve upon that workflow to increase DNA recovery from chromosome sorting as well as sequencing yield. We apply it to sequence and assemble the largest human chromosome - chromosome 1 - of a Chinese individual using a single Oxford Nanopore MinION flow cell. We generate a selective and highly continuous assembly whose continuity reaches into the order of magnitude of the human reference GRCh38. We then use this assembly to call candidate structural variants against the reference and find 685 putative novel SV candidates. We propose this workflow as a potential solution to assemble structurally complex chromosomes, or the study of very large plant or animal genomes that might challenge traditional assembly strategies.


  • Open Access

    Three-Dimensional Genomic Structure and Cohesin Occupancy Correlate with Transcriptional Activity during Spermatogenesis

    by Covadonga Vara, Andreu Paytuví-Gallart, Yasmina Cuartero, François Le Dily, Francisca Garcia, Judit Salvà-Castro, Laura Gómez-H, Eva Julià, Catia Moutinho, Riccardo Aiese Cigliano, et al.


  • Open Access

    Selective single molecule sequencing and assembly of a human Y chromosome of African origin

    by Lukas F. K. Kuderna, Esther Lizano, Eva Julià, Jessica Gomez-Garrido, Aitor Serres-Armero, Martin Kuhlwilm, Regina Antoni Alandes, Marina Alvarez-Estape, David Juan, Heath Simon, et al.

    Mammalian Y chromosomes are often neglected from genomic analysis. Due to their inherent assembly difficulties, high repeat content, and large ampliconic regions, only a handful of species have their Y chromosome properly characterized. To date, just a single human reference quality Y chromosome, of European ancestry, is available due to a lack of accessible methodology. To facilitate the assembly of such complicated genomic territory, we developed a novel strategy to sequence native, unamplified flow sorted DNA on a MinION nanopore sequencing device. Our approach yields a highly continuous assembly of the first human Y chromosome of African origin. It constitutes a significant improvement over comparable previous methods, increasing continuity by more than 800%. Sequencing native DNA also allows to take advantage of the nanopore signal data to detect epigenetic modifications in situ. This approach is in theory generalizable to any species simplifying the assembly of extremely large and repetitive genomes.


  • Correction: Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis

    by Montse Camiña-Tato, Carlos Morcillo-Suárez, Marta F Bustamante, Israel Ortega, Arcadi Navarro, Aura Muntasell, Miguel López-Botet, Alex Sánchez, Paco Carmona, Eva Julià, et al.

  • Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis

    by Montse Camiña-Tato, Carlos Morcillo-Suárez, Marta F. Bustamante, Israel Ortega, Arcadi Navarro, Aura Muntasell, Miguel López-Botet, Alex Sánchez, Paco Carmona, Eva Julià, et al.

    The granule-dependent exocytosis pathway is an important mechanism to induce apoptosis by CD8+ T cells and NK cells and involves lytic molecules such as perforin. In the current study, we investigated the perforin 1 gene (PRF1) as a candidate for multiple sclerosis (MS) susceptibility in the Spanish population. We genotyped three PRF1 single nucleotide polymorphisms (rs885822, rs10999426, and rs3758562) in 420 patients with MS and 512 controls. Associations of PRF1 polymorphisms with the disease were restricted to male patients with MS, and the finding was consistently observed at the allele, genotype, and haplotype levels. Gender-associated differences were validated in an additional replication cohort comprised of 292 MS cases and 300 controls. In addition, we identified minor risk haplotypes strongly associated with male patients having primary progressive MS (PPMS). Further characterization of male patients with PPMS carrying the risk haplotypes by means of gene expression microarrays revealed overrepresentation of the cell killing gene ontology category among downregulated genes in these patients compared with male patients with PPMS carrying protective haplotypes. Moreover, PRF1 mRNA expression levels were significantly lower in patients with risk haplotypes, and changes in perforin protein expression by CD8+ T cells mirrored those observed in gene expression. These findings suggest a gender dimorphism in the PRF1 association with MS and point to the presence of a generalized defect in the expression of genes that code for proteins involved in cell killing in a subgroup of male patients with PPMS.


  • Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis

    by M. Camiña-Tato, M. Fernández, C. Morcillo-Suárez, A. Navarro, E. Julià, M.C. Edo, X. Montalban, M. Comabella


  • Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS

    by Eva Julià, Mari Carmen Edo, Alex Horga, Xavier Montalban, Manuel Comabella


  • Plasma levels of 15d‐PGJ2 are not altered in multiple sclerosis

    by M. Comabella, J. M. Pradillo, M. Fernández, J. Río, I. Lizasoain, E. Julià, M. A. Moro, J. Sastre‐Garriga, X. Montalban

    Background: The 15-deoxi delta prostaglandin J2 (15d-PGJ2) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ2 may modulate multiple sclerosis (MS). Methods: Here, we investigated the plasma levels of 15d-PGJ2 by enzyme-linked immunoassay in 28 healthy controls and 140 MS patients [30 patients with primary-progressive MS, 28 patients with secondary-progressive MS, and 82 patients with relapsing-remitting MS (28 patients during clinical remission, 25 patients during relapse, and 29 treated with interferon-beta – IFN-β)]. Results: Levels of 15d-PGJ2 were similar between healthy controls and untreated MS patients with different clinical courses of the disease. Treatment with IFN-β had no effect on levels of 15d-PGJ2. Conclusions: Although these findings suggest that 15d-PGJ2 is not involved in the acute or chronic phases of the disease, further studies measuring 15d-PGJ2 in cerebrospinal fluid samples are needed before excluding a role of 15d-PGJ2 in MS.


  • Open Access

    A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

    by M. Comabella, J. D. Lünemann, J. Río, A. Sánchez, C. López, E. Julià, M. Fernández, L. Nonell, M. Camiña-Tato, F. Deisenhammer, et al.

    The effect of interferon-beta in multiple sclerosis is modest and many patients do not respond to treatment. To date, no single biomarker reliably correlates with responsiveness to interferon-β in multiple sclerosis. In the present study, genome-wide expression profiling was performed in peripheral blood mononuclear cells from 47 multiple sclerosis patients treated with interferon-β for a minimum of 2 years and classified as responders and non-responders based on clinical criteria. A validation cohort of 30 multiple sclerosis patients was included in the study to replicate gene-expression findings. Before treatment, interferon-β responders and non-responders were characterized by differential expression of type I interferon-induced genes with overexpression of the type interferon-induced genes in non-responders. Upon treatment the expression of these genes remained unaltered in non-responders, but was strongly upregulated in responders. Functional experiments showed a selective increase in phosphorylated STAT1 levels and interferon receptor 1 expression in monocytes of non-responders at baseline. When dissecting this type I interferon signature further, interferon-β non-responders were characterized by increased monocyte type I interferon secretion upon innate immune stimuli via toll-like receptor 4, by increased endogenous production of type I interferon, and by an elevated activation status of myeloid dendritic cells. These findings indicate that perturbations of the type I interferon signalling pathway in monocytes are related to lack of response to interferon-β, and type I interferon-regulated genes may be used as response markers in interferon-β treatment.